Abstract:Natural killer (NK) cells have the unique capacity to lyse tumor cells without the need for antigen specific receptors. Modulation of NK cell cytokine, chemokine, and activating and inhibitory receptor expression using gene regimens represents an attractive strategy to further bolster NK cell anti-tumor activity for the purpose of NK cell immunotherapy. Current efforts in clinical-grade genetic modification of patient-derived cells, used in immunotherapy protocols, rely on stable transduction mediated by viral vectors. However, primary NK cells are notoriously difficult to transduce using viral vectors. Here we describe a lentiviral vector-based approach that results in an efficient, robust, and highly reproducible method of stable gene transfer into primary human peripheral blood-derived NK cells, which can subsequently be expanded ex vivo for adoptive infusion into humans. In vitro experiments established highly efficient transduction of ex vivo expanded NK cells could be achieved by activation of primary NK cells in vitro for 2-4 days in cytokine containing media followed by transduction of activated NK cells using LV vectors 2-3 days before integration into our existing ex vivo expansion protocol using irradiated EBV-LCL feeder cells. Unless NK cells were first activated in cytokine-containing media, LV transduction was unsuccessful. Cytokine activation in media containing IL-2 for 2-4 days was found to be sufficient to achieve high transduction efficiency, while additional supplementation of the media with IL-15 or IL-21 had negligible effects. NK cell transduction efficiency and viability with the use of RetroNectin® was uniformly superior to polycation-based transduction protocols. In experiments where NK cells were transduced with identical lentiviral constructs with 8 different promoter sequences driving expression of EGFP, PGK, EFS, and SV40 promoters consistently demonstrated the highest transduction efficiencies reproducibly in the range of 25-60%. Remarkably, when transduced NK cells were stimulated ex vivo using a clinical grade irradiated EBV-LCL feeder cell line, 100-1000 fold expansions of transduced NK cells could be achieved with sustained transgene expression over two weeks. Transduced and expanded primary NK cells remained highly cytotoxic against K562 tumor targets without developing functional deficiencies in degranulation, IFNγ, or TNFα production. These data establish a simple method to produce large numbers (>1011) of genetically modified clinical grade NK cells suitable for infusion. The protocol described herein overcomes previous difficulties described with common transduction techniques opening new avenues to investigate the impact of adoptive infusion of primary NK cells stably transduced to express a variety of different transgenes of interest.

Study of Immuno-Activity Enhancement by Transduction of an NKG5 Splicing Variants into NK Cell

NKG5SV transduction enhances NK cell cytotoxic activity on hepatocellula r carcinoma

Transduction of an Splicing Varinats of Immuno-Protein NKG5 into NK Cell to Enhance Its Inhibition to Hepatocellular Carcinoma

Expansion of NK Cells by Engineered K562 Cells Co-Expressing 4-1BBL and Mmica, Combined with Soluble IL-21.

Use of NK Cell Transducted with NKG5-SV Gene to Inhibit Heaptocellular Carcinoma

Expression of NKG2D receptor and its effects on the cytotoxicity of NK cells in nude mice with transplanted human hepatocellular carcinoma

The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation

Expansion and Function of Human NK Cells Induced with Different Stimulating Factor Combinations Ex Vivo

Research into the expression of KIR on NK and T cells after HLA-mismatched hematopoitic cell transplantation

The Characterization of NK Cell Line Co-Transfected with Human Stem Cell Factor and Human Interleukin-15 Gene

Effectiveness of donor natural killer cell infusion in haplo-identical hematopoietic stem cell transplantation

In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells

Effect of NK cell on graft-versus-host disease in mouse allogeneic bone marrow transplantation

Experimental Study on IL-2-and IL-15 Appficafion in Allogeneic Hematopoiefic Stem Cell Transplantation

A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy

Expansion and activation of natural killer cells with specific cytotoxicity against multiple myeloma

Promoting sustainable proliferation of NK cells by up-regulating IL2 and IL12 through CRISPR-CAS9Promoting sustainable proliferation of NK cells by up-regulating IL2 and IL12 through CRISPR-CAS9

Nk Cell-Based Approach for Screening Novel Functional Immune Genes

Expansion of human natural killer cells with specific cytotoxicity against leukemia cells in vitro

High-Efficiency Lentiviral Genetic Modification of Primary Human Natural Killer Cells

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody